Neoadjuvant Intraarterial Chemotherapy Followed by Radical Hysterectomy and/or Radiotherapy for Locally Advanced Cervical Cancer

Sugiyama, Toru; Nishida, Takashi; Hasuo, Yasuyuki; Fujiyoshi, Keizo; Yakushiji, M

doi:10.1006/gyno.1998.4976

Cited by 35 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…regimen (Benedetti-Panici et al, 1991;Souhami et al, 1991;Vermorken, 1993;Scarabelli et al, 1995;Sundfor et al, 1996;Sugiyama et al, 1998a). In this study, we observed a response rate of 78%.…”

Section: Discussionsupporting

confidence: 65%

“…In recent years, cisplatincontaining chemotherapy has been used as neoadjuvant chemotherapy (NAC) to treat patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIb, III, or IV diseases as well as stage Ib or IIa disease with a bulky mass. NAC has been reported as useful in the control of local or regional disease, and is useful in controlling remote metastasis (BenedettiPanici et al, 1991;Souhami et al, 1991;Vermorken, 1993;Scarabelli et al, 1995;Sundfor et al, 1996;Sugiyama et al, 1998a). Recently, NAC followed by radical surgery has been proposed to improve the survival rate of patients with locally advanced cervical cancer (Benedetti-Panici et al, 1991;Scarabelli et al, 1995;Sugiyama et al, 1998a).…”

mentioning

confidence: 99%

“…NAC has been reported as useful in the control of local or regional disease, and is useful in controlling remote metastasis (BenedettiPanici et al, 1991;Souhami et al, 1991;Vermorken, 1993;Scarabelli et al, 1995;Sundfor et al, 1996;Sugiyama et al, 1998a). Recently, NAC followed by radical surgery has been proposed to improve the survival rate of patients with locally advanced cervical cancer (Benedetti-Panici et al, 1991;Scarabelli et al, 1995;Sugiyama et al, 1998a). Because the optimal NAC regimen has only recently been established, we need to develop a new combination chemotherapy regimen to achieve clinical benefits in the treatment of locally advanced cervical cancer.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

et al. 1999

View full text Add to dashboard Cite

) given intravenously on day 1. Treatment was repeated every 4 weeks for a total of two or three cycles. Among 23 eligible patients (median age: 59 years), three showed complete response (13%), 15 showed partial response (65%), for an overall response rate of 78% (95% confidence interval 58-90%). Stable disease was observed in four cases (17%) and progressive disease in one (4%). The median time to failure and median survival time have not yet been reached. Of the 52 treatment cycles administered, diarrhoea and grade 3 or 4 neutropenia were observed in 10% and 75% respectively. There were no therapy-related deaths. The combination of CPT-11 with cisplatin is a promising regimen for neoadjuvant chemotherapy in locally advanced cervical cancer. The toxicities of this regimen are well tolerated.

show abstract

Section: Discussionsupporting

confidence: 65%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Therefore, the prognosis of patients who have stage IIIb or IVa uterine cervical cancer based on the present therapeutic strategy with PPPEC was better compared with that of conventional therapy. Our findings were congruent to published reports demonstrating that the use of intra-arterial infusion was beneficial to patients with advanced uterine cervical cancer (Minegawa et al 1998, Sugiyama et al 1998, Fujiwaki et al 1999, Nagata et al 2000. The existence of lymph node metastasis is a poor prognostic factor in patients with cervical cancer (Terada et al 1988, Tinga et al 1992.…”

Section: Discussionsupporting

confidence: 91%

Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma

Maruo¹,

Motoyama²,

Hamana³

et al. 2008

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

“…Previous studies, usually performed with 3 cycles of platinum and taxanes, have shown the benefits of IANAC for controlling bulky cervical cancer. IANAC was effective at reducing tumor bulk, with reduced toxicity (relative to intravenous treatments), with safety and improved prognosis (3,(5)(6)(7)(8)(9).…”

Section: Discussionmentioning

confidence: 99%

Single-dose intra-arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB-IIB cervical cancer

Yoshino

Hosoi

Osuga

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Extended wait time prior to initial surgery may increase patients' anxiety. Therefore, patients may opt to receive other available treatments to inhibit tumor growth until surgery. This retrospective study describes our experience with single-dose intra-arterial neoadjuvant chemotherapy (IANAC) to more effectively utilize the wait time prior to radical hysterectomy. A total of 12 patients with International Federation of Gynecology and Obstetrics stage IB1-IIB cervical cancer were treated with single-dose IANAC prior to radical hysterectomy. Cisplatin and paclitaxel were administered intra-arterially or intravenously, respectively. The surgical outcome, prognosis and factors affecting disease recurrence were compared between these 12 patients and 57 patients in a primary surgery alone (PS) control group. As regards surgical outcome, there were no significant differences between the two groups. During the postoperative follow-up period (median, 41 months), disease recurrence was observed in 5̸12 (41.6%) IANAC cases and in 22̸57 (38.5%) PS cases (median follow-up, 54 months). There was no significant difference in disease-free survival (DFS) or 3-year survival rates between IANAC and PS (91.6 vs. 71.9%, respectively).The multivariate analysis demonstrated that wait time duration (≥45 vs. <45 days) and the use of IANAC did not affect DFS. Only tumor histology (squamous vs. non-squamous) was found to be an independent prognostic factor for DFS (hazard ratio = 0.35, 95% confidence inerval: 0.145-0.8967, P=0.0292). In addition, distal recurrence was statistically more frequent in the IANAC group compared with that in the PS group (P=0.0405). Therefore, single-cycle IANAC should not be performed without careful consideration.

show abstract

Neoadjuvant Intraarterial Chemotherapy Followed by Radical Hysterectomy and/or Radiotherapy for Locally Advanced Cervical Cancer

Cited by 35 publications

References 20 publications

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma

Single-dose intra-arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB-IIB cervical cancer

Contact Info

Product

Resources

About